Breye Therapeutics Concludes Promising Phase 1b Trial of Danegaptide for Diabetic Retinopathy Breye Therapeutics announces the successful completion of a Phase 1b trial for danegaptide, targeting diabetic retinopathy, showing promising results for patient treatment.

Breye Therapeutics Concludes Promising Phase 1b Trial of Danegaptide for Diabetic Retinopathy #Denmark #Copenhagen #Diabetic_Retinopathy #Breye_Therapeutics #danegaptide